vs
Pacira BioSciences, Inc.（PCRX）とPROGRESS SOFTWARE CORP（PRGS）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROGRESS SOFTWARE CORPの直近四半期売上が大きい（$252.7M vs $196.9M、Pacira BioSciences, Inc.の約1.3倍）。PROGRESS SOFTWARE CORPの前年同期比売上増加率が高い（17.5% vs 5.1%）。PROGRESS SOFTWARE CORPの直近四半期フリーキャッシュフローが多い（$59.9M vs $43.5M）。過去8四半期でPROGRESS SOFTWARE CORPの売上複合成長率が高い（17.0% vs 8.5%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
プログレスソフトウェアコーポレーションは、アプリケーション開発プラットフォーム、データ接続ツール、デジタルエクスペリエンスソリューションなどの企業向けソフトウェアを開発・販売しています。金融、医療、製造、小売など世界中の多様な業界の顧客にサービスを提供し、業務効率化と高性能業務アプリの構築を支援しています。
PCRX vs PRGS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $196.9M | $252.7M |
| 純利益 | — | $25.7M |
| 粗利率 | 79.5% | 81.6% |
| 営業利益率 | 1.2% | 15.2% |
| 純利益率 | — | 10.2% |
| 売上前年比 | 5.1% | 17.5% |
| 純利益前年比 | — | 2144.6% |
| EPS（希薄化後） | $0.05 | $0.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $196.9M | $252.7M | ||
| Q3 25 | $179.5M | $249.8M | ||
| Q2 25 | $181.1M | $237.4M | ||
| Q1 25 | $168.9M | $238.0M | ||
| Q4 24 | $187.3M | $215.0M | ||
| Q3 24 | $168.6M | $178.7M | ||
| Q2 24 | $178.0M | $175.1M | ||
| Q1 24 | $167.1M | $184.7M |
| Q4 25 | — | $25.7M | ||
| Q3 25 | $5.4M | $19.4M | ||
| Q2 25 | $-4.8M | $17.0M | ||
| Q1 25 | $4.8M | $10.9M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $-143.5M | $28.5M | ||
| Q2 24 | $18.9M | $16.2M | ||
| Q1 24 | $9.0M | $22.6M |
| Q4 25 | 79.5% | 81.6% | ||
| Q3 25 | 80.9% | 81.0% | ||
| Q2 25 | 77.4% | 80.1% | ||
| Q1 25 | 79.7% | 80.6% | ||
| Q4 24 | 78.7% | 83.0% | ||
| Q3 24 | 76.9% | 83.7% | ||
| Q2 24 | 75.1% | 81.7% | ||
| Q1 24 | 71.6% | 82.2% |
| Q4 25 | 1.2% | 15.2% | ||
| Q3 25 | 3.5% | 17.6% | ||
| Q2 25 | 4.7% | 16.3% | ||
| Q1 25 | 1.2% | 13.6% | ||
| Q4 24 | 13.2% | 10.0% | ||
| Q3 24 | -82.8% | 22.6% | ||
| Q2 24 | 15.9% | 15.5% | ||
| Q1 24 | 7.9% | 19.0% |
| Q4 25 | — | 10.2% | ||
| Q3 25 | 3.0% | 7.8% | ||
| Q2 25 | -2.7% | 7.2% | ||
| Q1 25 | 2.8% | 4.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | -85.1% | 15.9% | ||
| Q2 24 | 10.6% | 9.2% | ||
| Q1 24 | 5.4% | 12.3% |
| Q4 25 | $0.05 | $0.59 | ||
| Q3 25 | $0.12 | $0.44 | ||
| Q2 25 | $-0.11 | $0.39 | ||
| Q1 25 | $0.10 | $0.24 | ||
| Q4 24 | $0.38 | $0.01 | ||
| Q3 24 | $-3.11 | $0.65 | ||
| Q2 24 | $0.39 | $0.37 | ||
| Q1 24 | $0.19 | $0.51 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $238.4M | $94.8M |
| 総負債低いほど良い | $372.2M | $1.4B |
| 株主資本純資産 | $693.1M | $478.3M |
| 総資産 | $1.3B | $2.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.54× | 2.93× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $238.4M | $94.8M | ||
| Q3 25 | $246.3M | $99.0M | ||
| Q2 25 | $445.9M | $102.0M | ||
| Q1 25 | $493.6M | $124.2M | ||
| Q4 24 | $484.6M | $118.1M | ||
| Q3 24 | $453.8M | $232.7M | ||
| Q2 24 | $404.2M | $190.4M | ||
| Q1 24 | $325.9M | $133.2M |
| Q4 25 | $372.2M | $1.4B | ||
| Q3 25 | $376.7M | $1.4B | ||
| Q2 25 | $580.5M | $1.5B | ||
| Q1 25 | $583.4M | $1.5B | ||
| Q4 24 | $585.3M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $478.3M | ||
| Q3 25 | $727.2M | $477.7M | ||
| Q2 25 | $757.8M | $452.7M | ||
| Q1 25 | $798.5M | $431.8M | ||
| Q4 24 | $778.3M | $438.8M | ||
| Q3 24 | $749.6M | $425.6M | ||
| Q2 24 | $879.3M | $401.7M | ||
| Q1 24 | $892.2M | $461.7M |
| Q4 25 | $1.3B | $2.5B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.5B | $2.4B | ||
| Q1 25 | $1.6B | $2.5B | ||
| Q4 24 | $1.6B | $2.5B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.6B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.54× | 2.93× | ||
| Q3 25 | 0.52× | 2.97× | ||
| Q2 25 | 0.77× | 3.22× | ||
| Q1 25 | 0.73× | 3.50× | ||
| Q4 24 | 0.75× | 3.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $43.7M | $62.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $43.5M | $59.9M |
| FCFマージンFCF / 売上 | 22.1% | 23.7% |
| 設備投資強度設備投資 / 売上 | 0.1% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | — | 2.44× |
| 直近12ヶ月FCF直近4四半期 | $136.7M | $229.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $43.7M | $62.8M | ||
| Q3 25 | $60.8M | $73.4M | ||
| Q2 25 | $12.0M | $30.0M | ||
| Q1 25 | $35.5M | $68.9M | ||
| Q4 24 | $33.1M | $19.7M | ||
| Q3 24 | $53.9M | $57.7M | ||
| Q2 24 | $53.2M | $63.7M | ||
| Q1 24 | $49.1M | $70.5M |
| Q4 25 | $43.5M | $59.9M | ||
| Q3 25 | $57.0M | $72.4M | ||
| Q2 25 | $9.3M | $29.5M | ||
| Q1 25 | $26.9M | $67.7M | ||
| Q4 24 | $31.0M | $16.8M | ||
| Q3 24 | $49.8M | $56.6M | ||
| Q2 24 | $51.6M | $62.7M | ||
| Q1 24 | $46.3M | $70.2M |
| Q4 25 | 22.1% | 23.7% | ||
| Q3 25 | 31.7% | 29.0% | ||
| Q2 25 | 5.1% | 12.4% | ||
| Q1 25 | 15.9% | 28.4% | ||
| Q4 24 | 16.6% | 7.8% | ||
| Q3 24 | 29.6% | 31.7% | ||
| Q2 24 | 29.0% | 35.8% | ||
| Q1 24 | 27.7% | 38.0% |
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 2.2% | 0.4% | ||
| Q2 25 | 1.5% | 0.2% | ||
| Q1 25 | 5.1% | 0.5% | ||
| Q4 24 | 1.1% | 1.3% | ||
| Q3 24 | 2.4% | 0.6% | ||
| Q2 24 | 0.9% | 0.5% | ||
| Q1 24 | 1.7% | 0.2% |
| Q4 25 | — | 2.44× | ||
| Q3 25 | 11.20× | 3.78× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | 7.37× | 6.30× | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | 2.82× | 3.93× | ||
| Q1 24 | 5.47× | 3.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
